Bernard Gilly has over thirty years of continuous engagement in the foundation, management and/or funding of innovative companies in the fields of biopharmaceuticals, medical and information technologies.

In 2015, he created iBionext with the aim of building an innovation ecosystem to develop healthcare start-ups in France. Within iBionext, Bernard co-founded several high potential companies in the biotech and medtech space. He co-founded BrainEver in 2015 and since served as CEO for the company. He is CEO of GenSight Biologics (2012), and non-executive chairman of Pixium Vision (2011), Tissium (2013), Prophesee, Chronolife (2015) and Tilak Healthcare (2016). Prior to that, Bernard Gilly was Chairman and CEO of Fovea Pharmaceuticals, a company he founded in 2005 and sold to Sanofi in 2009 for €370m, becoming Sr VP of the Ophthalmology Division of Sanofi until 2012. From 2000 to 2005, Bernard Gilly was a Partner at Sofinnova Partners. He founded and invested in several companies, including Fovea (France), Sequoia Pharmaceuticals (USA), Faust Pharmaceuticals (France, now Domain Therapeutics) and Cellzome (Germany). Prior to joining Sofinnova, Bernard Gilly was President and CEO of Transgene, a company he drove from its early financing round in 1994 to its dual listing on the Nasdaq and the Nouveau Marché (Now Euronext-C) in1998, successfully raising €160m. Before Transgene, Bernard Gilly spent 6 years as VP R&D at Pasteur-Mérieux-Connaught, now Sanofi Pasteur.

Experience

• CEO (2015 - present)

  BrainEver

• Chairman (2015 - present)

  iBionext

• CEO (2013 - present)

  GenSight Biologics

• Founder & Chairman (2011 - 2024)

  Pixium Vision